Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.
- DOI
- 10.1182/blood.2025032422
- Published
- 2026 Aug 6
- Container
- Blood
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1182/blood.2025032422,
title = {Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.},
author = {Budde LE and Kamdar M and Assouline SE and Chavez JC and Ghosh N and Ollila TA and Hodson DJ and Modi D and Bastos-Oreiro M and Naik SG and Nakhoda SK and Lee Batlevi C and Wang J and Makadia S and Kwan A and Penuel E and Jing J and Wu H and Ead W and Pham S and To I and Wei MC and Wang ML},
year = {2026},
journal = {Blood},
doi = {10.1182/blood.2025032422},
url = {https://doi.org/10.1182/blood.2025032422}
}RIS
TY - JOUR TI - Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study. AU - Budde LE AU - Kamdar M AU - Assouline SE AU - Chavez JC AU - Ghosh N AU - Ollila TA AU - Hodson DJ AU - Modi D AU - Bastos-Oreiro M AU - Naik SG AU - Nakhoda SK AU - Lee Batlevi C AU - Wang J AU - Makadia S AU - Kwan A AU - Penuel E AU - Jing J AU - Wu H AU - Ead W AU - Pham S AU - To I AU - Wei MC AU - Wang ML PY - 2026 JO - Blood DO - 10.1182/blood.2025032422 UR - https://doi.org/10.1182/blood.2025032422 ER -
APA
LE, B., M, K., SE, A., JC, C., N, G., TA, O., DJ, H., D, M., M, B., SG, N., SK, N., C, L. B., J, W., S, M., A, K., E, P., J, J., H, W., W, E., S, P., I, T., MC, W., & ML, W. (2026). Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.. Blood. https://doi.org/10.1182/blood.2025032422
Source records
- pubmed · retrieved 2026-09-25T18:41:44.177Z